![](https://factor-h.org/wp-content/uploads/2024/07/Screenshot-2024-07-10-at-14.20.40-300x168.png)
Uniqure’s AMT-130 Phase 1/2 trial – a reflection
Yesterday, Uniqure reported on the 24-month results of their Phase 1/2 clinical trial with AMT-130, a viral gene therapy trial for HTT lowering for the
Yesterday, Uniqure reported on the 24-month results of their Phase 1/2 clinical trial with AMT-130, a viral gene therapy trial for HTT lowering for the
From a gene mutation to a lethal disease HD is caused by a single mutation in a region of the HTT gene, located at the
Dilia Oviedo Güillín, a woman of unwavering spirit and strength, always dreamed of reuniting her deceased husband and children in a place where they could
Team work and scientific education Every year, Factor-H Vice President Roger Cachope and I visit the Colombian & Venezuelan communities at least once, and over
Factor-H offers a free-of-charge legal assistance service in Colombia, with the sole objective of facilitating access to the services, medicines and supplies that the Colombian
Health ‘on board’ for Barranquitas It is exciting to see the joy and willingness with which our volunteers and community service go to the health
Factor-H is a registered 501-(c)3 non-profit foundation in the United States (EIN 82-5395108)